GleamWall
中文EN

VTRS Viatris Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1792044 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY4.3%
TTM net income YoY—
TTM EPS YoY83.1%
Revenue 3-yr CAGR-1.6%
Net income 3-yr CAGR—

Margins

Gross margin35.3%
Operating margin-0.0%
Net margin—
FCF margin14.3%
EBITDA margin19.1%

Returns

ROE—
ROA—
ROIC (approx.)-0.0%
Asset turnover0.41x

Leverage & solvency

Liabilities / assets60.5%
Debt / equity0.97x
Current ratio1.55x
Interest coverage-0.01x

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q2*2026-06-302026Q1*2026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q1*2025-03-312024Q4*2024-12-31
Income statement
Revenue$3.75B$3.76B$3.52B$3.70B$3.76B$3.58B$3.25B$3.53B
Cost of revenue$2.31B$2.30B$2.36B$2.56B$2.39B$2.25B$2.09B$2.31B
Gross profit$1.44B$1.46B$1.16B$1.15B$1.37B$1.33B$1.16B$1.22B
R&D expense$231.70M$248.30M$248.60M$274.70M$250.40M$218.80M$222.00M$206.50M
SG&A expense$950.80M$1.13B$928.80M$1.03B$886.60M$928.70M$948.10M$1.05B
Operating income$261.50M$6.30M-$79.70M-$192.70M$178.80M$233.00M-$2.88B-$179.80M
Interest expense$112.40M$120.70M$120.10M$119.60M$119.60M$116.60M$115.50M$120.20M
Pretax income$127.90M-$64.00M-$247.30M-$343.00M-$7.90M-$217.10M-$3.10B-$526.50M
Income tax$453.20M$54.80M-$423.70M-$2.90M$120.30M-$212.50M-$55.00M-$10.00M
Net income-$325.30M-$118.80M$176.40M—-$128.20M-$4.60M-$3.04B—
EBITDA$958.70M$678.60M$596.40M$574.10M$867.30M$911.30M-$2.22B$566.40M
EPS (basic)-0.28-0.100.15—-0.110.00-2.55—
EPS (diluted)-0.28-0.100.15—-0.110.00-2.55—
Dividends declared per share0.120.120.120.120.120.120.120.12
Weighted avg. shares (diluted)1.15B1.16B1.18B—1.16B1.17B1.19B—
Balance sheet
Cash & equivalents$1.79B$886.50M$1.80B$1.32B$975.30M$566.40M$755.00M$736.10M
Short-term investments———$40.70M———$38.00M
Receivables$3.12B$3.13B$3.08B$3.03B$3.37B$3.26B$3.13B$3.22B
Inventory$3.83B$3.93B$3.93B$4.00B$4.11B$4.26B$4.10B$3.85B
Current assets$10.30B$10.06B$10.92B$9.79B$9.95B$9.77B$9.62B$9.52B
PP&E, net$2.42B$2.44B$2.53B$2.61B$2.63B$2.64B$2.64B$2.67B
Goodwill$6.62B$6.65B$6.69B$6.75B$6.73B$6.75B$6.46B$9.13B
Intangibles$13.08B$13.68B$14.48B$15.10B$15.72B$16.32B$16.66B$17.07B
Total assets$34.68B$35.04B$36.83B$37.19B$37.92B$38.41B$38.47B$41.50B
Current liabilities$6.64B$6.35B$6.81B$7.09B$7.36B$7.13B$5.72B$5.78B
Short-term debt$1.72B$1.74B$1.93B$1.93B$1.94B$1.67B$700,000$600,000
Long-term debt$11.59B$11.61B$12.41B$12.48B$12.49B$12.79B$14.18B$14.04B
Total debt$13.31B$13.35B$14.34B$14.41B$14.43B$14.46B$14.18B$14.04B
Total liabilities$21.00B$20.78B$22.18B$22.48B$22.70B$22.84B$22.82B$22.87B
Shareholders' equity$13.69B$14.26B$14.66B$14.71B$15.22B$15.57B$15.65B$18.64B
Net debt$11.52B$12.46B$12.54B$13.09B$13.46B$13.90B$13.42B$13.30B
Cash flow statement
Operating cash flow$899.40M$381.80M$388.30M$815.80M$744.90M$219.70M$535.50M$482.70M
Capital expenditure$85.70M$52.80M$39.90M$196.50M$86.80M$52.90M$42.60M$140.40M
Free cash flow$813.70M$329.00M$348.40M$619.30M$658.10M$166.80M$492.90M$342.30M
Investing cash flow$292.30M-$51.60M$277.40M-$211.20M-$98.90M-$52.50M-$65.10M-$168.70M
Financing cash flow-$289.80M-$1.24B-$203.80M-$236.40M-$228.10M-$362.40M-$467.00M-$1.42B
Depreciation & amortization$697.20M$672.30M$676.10M$766.80M$688.50M$678.30M$664.70M$746.20M
Stock-based compensation$39.60M$38.70M$48.20M$49.40M$36.00M$37.10M$55.20M$32.30M
Share buybacks$150.00M$150.00M$0$85.10M$67.90M$175.00M$175.40M$0

Free plan shows the latest 8 periods; Pro shows all 32 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.